On Sept. 8, 2022, researchers from the University of Oxford and their partners reported findings from their Phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21/Matrix-Mﾙ ﾖ which previously demonstrated high-level efficacy of 77% over the following 12 months in young west African children in 2021.

In their findings (reported in The Lancet Infectious Diseases), they found that a vaccine booster dose at one year following a primary three-dose regime maintained high efficacy against malaria, and continued to meet the World Health Organizationﾒs Malaria Vaccine Technology Roadmap goal of a vaccine with at least 75% efficacy.